Phase I Study of Lonsurf in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Investigating the Safety and Effects of a Chemotherapy Combination for Pancreatic Cancer

Recruiting
18 years - 100 years
All
1 Location

Brief description of study.

The purpose of this study is to see whether a chemotherapy drug called Lonsurf (TAS-102) could be given safely with other chemotherapy agents (gemcitabine and nab-paclitaxel), and to assess the good and bad effects this treatment might have. Gemcitabine and nab-paclitaxel are approved by the Food and Drug Administration (FDA) for the treatment of pancreatic cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: pancreatic cancer,Pancreatic Ductal Adenocarcinoma
  • Age: 18 years - 100 years
  • Gender: All

Inclusion Criteria

Untreated locally advanced PDAC
Histologically or cytologically confirmed PDAC
Adequate organ function
Women of childbearing potential definition (WOCBP) must have a negative serum or urine pregnancy test performed within 14 days prior to initiation of study treatment.

Updated on 19 Feb 2024. Study ID: 1811447298 (IUSCC-0664)

This study investigates the safety and effects of combining an investigational medication with other chemotherapy agents for the treatment of pancreatic cancer. Pancreatic cancer is a disease where cells in the pancreas grow uncontrollably. The purpose of this study is to see how well this combination works and to identify any side effects.

Participants in the study will receive a combination of chemotherapy treatments. Chemotherapy is a type of cancer treatment that uses drugs to stop the growth of cancer cells. The study will involve regular monitoring and assessments to evaluate the treatment's impact on the participants.

  • Who can participate: Adults with untreated locally advanced pancreatic cancer, confirmed through tests, can participate. Participants must have adequate organ function and women of childbearing potential must test negative for pregnancy before starting the study.
  • Study details: Participants will receive a combination of chemotherapy drugs, including an investigational medication. The treatment will be administered under close supervision to monitor safety and effects.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here